FuelCell Energy Inc (NASDAQ:FCEL), Portola Pharmaceuticals Inc (NASDAQ:PTLA) and Vector Group Ltd (NYSE:VGR) are three companies from diverse industry sectors that have recently seen insider buying activity. While FuelCell Energy Inc (NASDAQ:FCEL) and Vector Group Ltd (NYSE:VGR) saw insider buying from officers of the company, a large shareholder bought a large amount Portola Pharmaceuticals Inc (NASDAQ:PTLA)’s shares. Let’s explore each deal in detail.
FuelCell Energy Inc (NASDAQ:FCEL) is a $520 million clean energy company. On October 7, John A Rolls, Chairman of FuelCell Energy Inc (NASDAQ:FCEL), purchased 100,000 shares of the company at an average price of $1.88 per share. With this purchase, Rolls now owns a total of 968,000 shares of the company. For the nine months ended July 31, 2014, the company reported a negative EPS of $0.12, compared to negative EPS of $0.14 for the same period of the previous year. Ken Brodkowitz and Mike Vermut’s Newland Capital and Cliff Asness’ AQR Capital Management are two institutional investors that hold shares of FuelCell Energy Inc (NASDAQ:FCEL) and as of June 30, 2014, own over 850,000 shares and 475,000 shares in the company, respectively.
Vector Group Ltd (NYSE:VGR) is a $2.18 billion, cigarettes manufacturing company. On October 8, Bryant J Kirkland III, CFO of Vector Group Ltd (NYSE:VGR), purchased 1,200 shares of the company at an average price of $20.53 and 698 shares of the company at $20.52 per share. Kirkland’s total ownership of Vector Group Ltd (NYSE:VGR)’s stock comes at 104,000 following the recent buys. Hedge funds that are bullish on this stock include David Rodriguez-Fraile’s Bluemar Capital Management and Rod Hinze’s Keypoint Capital Management. Bluemar Capital Management owned 437,000 shares of the company and Keypoint Capital Management owned over 344,000 shares of the company at the end of second quarter of 2014. Vector Group Ltd (NYSE:VGR) reported an EPS of $0.08 in the second quarter of 2014, compared to $0.14 in the same quarter of last year and currently trades at 57.4 times its earnings.
Portola Pharmaceuticals Inc (NASDAQ:PTLA) is a $1.26 billion market cap, biopharmaceutical company. On October 8, Maxwell (Mauritius) Pte Ltd, a large shareholder of Portola Pharmaceuticals Inc (NASDAQ:PTLA) purchased 1.6 million shares at an average price of $26.00per share. After this acquisition, Maxwell (Mauritius) Pte Ltd now owns over 5.83 million shares or 12.2% of all shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA). As of June 30, 2014, Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management and Samuel Isaly’s Orbimed Advisors owns over 1.3 million shares each of Portola Pharmaceuticals Inc (NASDAQ:PTLA), making them one of the largest institutional investors in the company. Portola Pharmaceuticals Inc (NASDAQ:PTLA) reported a negative EPS of $0.76 for the second quarter of 2014, compared to negative EPS of $1.47 for the same period last year.
Disclosure: None
Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.
